Noting that this research is still in it’s early stages, we will be following the work from the team at Queensland’s QIMR Berghofer with interest as the research and development progress.
A cutting-edge vaccine candidate developed by QIMR Berghofer has achieved potent and durable immune protection against Epstein–Barr virus (EBV) in pre-clinical models, a breakthrough that could prevent the type of severe viral infection known to be a leading cause of several diseases including multiple sclerosis and various cancers.
The early findings have been published in the prestigious journal Nature Communications.
https://www.qimrberghofer.edu.au/news/vaccine-breakthrough-offers-hope-against-ebv-associated-cancers-and-ms/